Association between Ultrasound-Based Metabolic Dysfunction-Associated Steatotic Liver Disease and Systemic Atherosclerosis: Insights from Carotid Ultrasound and Coronary Computed Tomography Findings
- Author:
Seong Hee KANG
1
;
SungA BAE
;
Hye Yeon CHON
;
Hyo Jung CHO
;
Eun Ju KIM
;
Seong Kyun NA
;
Jae Young JANG
;
Soon Koo BAIK
;
Hyung Joon YIM
;
On behalf of the Research Committee of KACU
Author Information
- Publication Type:Original Article
- From: Clinical Ultrasound 2025;10(2):98-108
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Background/Aims:Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant risk factor for cardiovascular disease. This study aimed to evaluate differences in carotid atherosclerosis and coronary artery disease severity according to MASLD subtypes using general health screening data from multiple tertiary hospitals.
Methods:A total of 3,466 subjects who underwent health check-ups including abdominal ultrasound, carotid ultrasound, and cardiac computed tomography were analyzed. Participants were categorized into non-SLD, MASLD, metabolic dysfunction-associated alcohol-relat-ed liver disease (MetALD), and alcohol-related liver disease. Carotid plaque prevalence and coronary artery stenosis severity were compared across groups and stratified by fibrosis stage using the Fibrosis-4 index (FIB-4).
Results:Patients with MASLD and MetALD showed a significantly higher prevalence of carotid plaques compared with the non-SLD group. The severity of coronary artery stenosis was also greater in MASLD and MetALD, particularly among those with advanced fibrosis (FIB-4 ≥2.67).
Conclusions:MASLD and MetALD are associated with increased burden of systemic atherosclerosis and coronary artery disease, especially in patients with advanced fibrosis. These findings highlight the importance of cardiovascular risk assessment in individuals with MASLD and its subtypes.
